Since subclonal TP53 alterations are likely acquired late during endometrioid carcinoma progression, the likelihood of p53 aberrancy in AH/EIN, an early stage of endometrial carcinoma development, is likely low, as further confirmed by studies [26,86]. Here, TP53 is linked to endometrial carcinoma.